DDD2
DDD2 is a selective and potent VHL-mediated PROTAC NUDT5 degrader. DDD2 induces robust NUDT5 degradation. DDD2 can be used in cancer research, such as lymphocytic leukemia and osteosarcoma[1]. (Structure Note: Pink: NUDT5 inhibitor (HY-176262) ; Blue: E3 (HY-125845) ; Black: linker (HY-W001958) )
Product Specifications
UNSPSC
12352005
Target
PROTACs
Related Pathways
PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C([C@H]1N(C[C@@H](C1)O)C([C@H](C(C)(C)C)NC(CCCCCCC(N2CCN(CC2)C3=NC4=C(C(N(C(N4C)=O)C)=O)N3CC5=NN=C(O5)C6=CC(OC)=C(C=C6)C)=O)=O)=O)NCC(C=C7)=CC=C7C(SC=N8)=C8C
Molecular Formula
C52H66N12O9S
Molecular Weight
1035.22
References & Citations
[1]Seher Alam, et al. A cell-based degrader assessment platform facilitates discovery of functional NUDT5 PROTACs. bioRxiv. June 19, 2025.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Von Hippel-Lindau (VHL)
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items